A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 patients with secondary Carbapenem Resistant Acinetobacter baumannii (CRAB) on an emergency basis Now the FDA has granted APT an Expanded […]
Press Releases
FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections
PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients
November 02, 2020 11:00 AM Eastern Standard Time Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated Significant increased mortality has been observed from secondary CRAB infections in COVID-19 patients APT and its partners are currently self-funding emergency use of PhageBank™ in this patient group, and are seeking […]
Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections
October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]
Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine
August 20, 2020 11:09 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus […]
Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing
— Proceeds to fund clinical trial for PhageBank treatment in periprosthetic joint infections — August 05, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed […]
Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test
— Assay to rapidly match therapeutic phage to antibiotic-resistant infections — June 09, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a […]
FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
— Three Clinical Sites to Enroll Patients with Recurrent and Complicated Urinary Tract Infections — March 12, 2020 10:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and […]
Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program
–Company is Recognized Top 1% among 4,000 applicants from 133 Countries– February 10, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate […]
Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense
Funds Designated to Support Clinical Development of PhageBankTM Precision Bacteriophage Therapeutic January 08, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of […]
Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress
–CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– October 30, 2019 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder […]